Cyclone-3000

Fully Automated Chemiluminescent Immunoassay Analyzer

Product Highlights

Detection method: Acridinium ester chemiluminescence

Sample types: Serum, plasma, urine, and more

Testing modes: Random, batch, and priority (STAT)

Reaction handling: Automatic cup loading and alignment

Calibration: Up to 8-point calibration with 2-point verification

Reagent storage: 2–8 °C refrigerated with automatic bead resuspension

Incubation: Stable 37 °C with multiple reaction modes

Magnetic processing: Automated separation, washing, and mixing

Monitoring: Liquid level, clog detection, anti-collision, and status alarms

Connectivity: LIS bidirectional communication and cloud management

Key Highlights

Temperature-Controlled Incubation

Honeycomb incubation design; PID-controlled at 37 ± 0.2 °C

Cost-Effective

Benchmarked against Mindray CL-900i

Innovative Mixing/Washing Technology

Magnetic separation & washing: Surrounding array design for efficient washing

Performance Specifications

Minimum sample volume

5 μL

Throughput

200 tests/hour

Sample positions

Incubation temperature

37 ± 0.2 °C

Repeatability

CV ≤ 3%

Reaction cups

500

Carryover (contamination) rate

< 1 ppm

Time to first result

≤ 13 min

CycloneSun-3000 Test Clinical Significance

Item

Concise Clinical Significance

Registration Certificate No.

PCT

TBD

IL-6

TBD

HBP

TBD

Myo

TBD

cTnT

TBD

CKMB

TBD

ST2

TBD

NT-proBNP

TBD

Novel Cardiac Biomarker ST2

Single cut-off value:

35 ng/mL

Clinical relevance:

Reflects myocardial fibrosis progression

Low interference:

Not affected by age, ethnicity, BMI, renal function, heart failure history, or atrial fibrillation

Biological stability:

High stability and consistency

Cardiac Biomarker ST2 Targeted Populations

Acute and chronic heart failure, myocardial infarction, myocardial fibrosis, and high-risk cardiovascular groups
Patients receiving renal dialysis (70% of dialysis patients die of heart failure)
ST2 can serve as a complement to BNP, especially under the premise of clear medical insurance requirements regarding BNP testing